(9 intermediate revisions by the same user not shown) | |||
Line 678: | Line 678: | ||
} | } | ||
− | + | .header_test { | |
− | . | + | background-position: top; |
− | + | background-attachment: fixed; | |
− | + | background-repeat: no-repeat; | |
− | + | -webkit-background-size: cover; | |
− | + | -moz-background-size: cover; | |
− | + | -o-background-size: cover; | |
− | + | background-size: cover; | |
− | + | padding-top: 100vh; | |
− | + | background-image: url("https://static.igem.org/mediawiki/2017/7/77/T--Chalmers-Gothenburg--Achievements_Biobricks.jpg"); | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | /*A lot of code for the line between the header and the body */ | |
− | + | border-bottom: 3px solid transparent; | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
-moz-border-image: -moz-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%);*/ | -moz-border-image: -moz-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%);*/ | ||
-webkit-border-image: -webkit-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%)*/ | -webkit-border-image: -webkit-linear-gradient(left, #000000 0%, #404040, #000000 100%); /*(left, #016243 0%, #b5deca, #016243 100%)*/ | ||
Line 730: | Line 704: | ||
} | } | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | + | /* Banner: name of the page */ | |
− | + | #banner { | |
− | + | height: 100%; | |
− | + | position: relative; | |
− | + | bottom: 50px; | |
− | + | float: left; | |
− | + | width: 100%; | |
− | + | font-size: 80pt; /*35pt*/ | |
− | + | font-family:"Lato", cursive; | |
− | + | color:#c91a03 ; | |
− | + | line-height: 65pt; | |
− | + | text-shadow: 5px 5px #000000; | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
} | } | ||
− | + | #banner h3 { | |
− | + | display: block; | |
− | + | position: absolute; | |
− | + | bottom: 50px; | |
− | + | left: 200px; | |
− | + | font-size: 80pt; /*35pt*/ | |
− | /* | + | font-family:"Lato", cursive; |
+ | color:#c91a03 ; | ||
+ | line-height: 65pt; | ||
+ | text-shadow: 5px 5px #000000; | ||
+ | /*border-style:dashed;*/ | ||
+ | padding: 20px 20px 20px 20px; | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
} | } | ||
− | + | #banner h4 { | |
− | + | display: block; | |
− | + | position: absolute; | |
− | + | bottom: -40px; | |
− | + | left: 200px; | |
− | + | font-size: 40pt; /*35pt*/ | |
− | + | font-family:"Lato", cursive; | |
− | + | color:#c91a03 ; | |
− | + | line-height: 65pt; | |
− | + | text-shadow: 3px 3px #000000; | |
− | + | /*border-style:dashed;*/ | |
− | + | padding: 20px 20px 20px 20px; | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
} | } | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
.header-text { | .header-text { | ||
Line 1,202: | Line 941: | ||
p a:visited { | p a:visited { | ||
+ | text-decoration: none; | ||
+ | color: #c91a03; | ||
+ | } | ||
+ | |||
+ | |||
+ | |||
+ | td a:link { | ||
text-decoration: none; | text-decoration: none; | ||
color: #c91a03; | color: #c91a03; | ||
} | } | ||
+ | |||
+ | td a:link:hover { | ||
+ | color: #7e1002; | ||
+ | } | ||
+ | |||
+ | td a:visited { | ||
+ | text-decoration: none; | ||
+ | color: #c91a03; | ||
+ | } | ||
+ | |||
h1 a:link { | h1 a:link { | ||
Line 1,595: | Line 1,351: | ||
<a href="https://2017.igem.org/Team:Chalmers-Gothenburg/InterLab">Interlab study</a> | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/InterLab">Interlab study</a> | ||
<hr> | <hr> | ||
− | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Achievements/medal"> | + | <a href="https://2017.igem.org/Team:Chalmers-Gothenburg/Achievements/medal">Accomplishments</a> |
</div> | </div> | ||
</li> | </li> | ||
Line 1,627: | Line 1,383: | ||
− | <div class=" | + | <div class="header_test"> |
− | + | <!-- Banner --> | |
− | + | <div id="banner"> | |
− | + | <h3>Biobricks</h3> | |
+ | </div> | ||
+ | </div> | ||
<div class="wrap-content"> | <div class="wrap-content"> | ||
− | + | <h4 class="subtitle">Parts summary</h4> | |
− | + | ||
+ | <h2> | ||
+ | Submitted parts | ||
+ | </h2> | ||
<p class="text"> | <p class="text"> | ||
− | + | Table 1 shows the parts that were submitted. All biobrick parts work in <i>S. cerevisiae</i> and are compatible with the RFC[10] standard. | |
− | + | ||
− | + | ||
− | + | ||
</p> | </p> | ||
− | + | ||
− | + | <figure> | |
− | + | <figcaption class="table-caption"><b>Table 1.</b> The Basic Parts which were submitted.</figcaption> | |
− | + | <table> | |
− | + | <tr> | |
+ | <th><b>Name</b></th> <th><b>Type</b></th> <th><b>Description</b></th> <th><b>Designer</b></th> <th><b>Length</b></th> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td><a href="http://parts.igem.org/Part:BBa_K2329000" target="blank">BBa_K2329000</a></td> <td>Regulation</td> <td>Cre-lox recombination with lox66 and lox71</td> <td>Alex Hedin</td> <td>473 bp</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td><a href="http://parts.igem.org/Part:BBa_K2329001" target="blank">BBa_K2329001</a></td> <td>RNA</td> <td>gRNA, deletion in <i>STE2</i></td> <td>Alex Hedin</td> <td>388 bp</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td><a href="http://parts.igem.org/Part:BBa_K2329002" target="blank">BBa_K2329002</a></td> <td>RNA</td> <td>gRNA, deletion in <i>STE3</i></td> <td>Alex Hedin</td> <td>388 bp</td> | ||
+ | </tr> | ||
+ | </table> | ||
+ | </figure> | ||
+ | |||
<h2> | <h2> | ||
− | + | Improvement of a previous biobrick part | |
</h2> | </h2> | ||
<p class="text"> | <p class="text"> | ||
− | + | <a href="http://parts.igem.org/Part:BBa_K2329000" target="blank">BBa_K2329000</a> is an improvement of the earlier biobrick part, <a href="http://parts.igem.org/Part:BBa_K740000" target="blank">BBa_K740000</a>. The improvement of the cre-lox recombinase system was done by changing the loxP site from reversible switch to a non-reversible switch. The loxP sites flanking the promoter was changed to mutated loxP sites, see Figure 1 [1]. The new mutant loxP sites (lox66 and lox71) have showed great success since the direction of the promoter did not flip back. | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</p> | </p> | ||
+ | <figure> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/e/e1/T--Chalmers-Gothenburg--LoxP_biobricks.png" style="height:50%; width:50%;"> | ||
+ | <figcaption><b>Figure 1.</b> Illustrated figure of the non-reversible flip. When the double mutant loxP site is produced through recombination, the promoter will not be able to flip back.</figcaption> | ||
+ | </figure> | ||
<h2> | <h2> | ||
− | + | Central parts which worked as expected | |
</h2> | </h2> | ||
<p class="text"> | <p class="text"> | ||
− | + | <a href="http://parts.igem.org/Part:BBa_K2329001" target="blank">BBa_K2329001</a> and <a href="http://parts.igem.org/Part:BBa_K2329002" target="blank">BBa_K2329002</a> are two central parts of our project, as replacing the native GPCRs STE2 and STE3 is vital to ensure that the only GPCR present on the yeast cell is the heterologous GPCR introduced by us. | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</p> | </p> | ||
+ | <h2> | ||
+ | Non submitted parts | ||
+ | </h2> | ||
+ | <p class="text"> | ||
+ | Table 2 shows the Basic Parts which were not submitted due to time constraints. We chose to present them here anyway to perhaps help studies for iGEM teams in the future. | ||
+ | </p> | ||
+ | |||
+ | <figure> | ||
+ | <figcaption class="table-caption"><b>Table 2.</b> The Basic Parts which were not submitted.</figcaption> | ||
+ | <table> | ||
+ | <tr> | ||
+ | <th><b>Name</b></th> <th><b>Type</b></th> <th><b>Description</b></th> <th><b>Designer</b></th> <th><b>Length</b></th> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td><a href="http://parts.igem.org/Part:BBa_K2329003" target="blank">BBa_K2329003</a></td> <td>Coding</td> <td>GPCR, Ri7</td> <td>Alex Hedin</td> <td>984 bp</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td><a href="http://parts.igem.org/Part:BBa_K2329004" target="blank">BBa_K2329004</a></td> <td>Coding</td> <td>GPCR, Olfr1258</td> <td>Alex Hedin</td> <td>936 bp</td> | ||
+ | </tr> | ||
+ | </table> | ||
+ | </figure> | ||
<h2> | <h2> | ||
− | + | Characterization of BBa_K2329004 | |
</h2> | </h2> | ||
<p class="text"> | <p class="text"> | ||
− | + | <a href="http://parts.igem.org/Part:BBa_K2329004" target="blank">BBa_K2329004</a> was another part that got characterized. We incorporated a mouse GPCR called Olfr1258 into <i>S. cerevisiae</i> which showed successful results in membrane localization and response to its ligand 2-butanone. | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</p> | </p> | ||
− | + | ||
− | + | <h4 class="sidetitle">References</h4> | |
− | + | ||
+ | <div class="reference_list"> | ||
+ | <ul> | ||
+ | <li>[1]   Spehr M, Munger S. Olfactory receptors: G protein-coupled receptors and beyond. Journal of Neurochemistry [Internet]. 2009 [cited 10 October 2017];109(6):1570-1583. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19383089 | ||
+ | </li> | ||
+ | </ul> | ||
+ | </div> | ||
</div> <!--------------------------- HTML STOP --------------------------------> | </div> <!--------------------------- HTML STOP --------------------------------> | ||
Line 1,702: | Line 1,490: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="https://www.agilent.com/home" target="_blank"> | <a href="https://www.agilent.com/home" target="_blank"> | ||
− | <img src="" alt="Agilent Technologies" class="footerimg on"> | + | <img src="https://static.igem.org/mediawiki/2017/f/fb/T--Chalmers-Gothenburg--Agilent_gray.png" alt="Agilent Technologies" class="footerimg on"> |
− | <img src="" alt="Agilent Technologies" class="footerimg off"> | + | <img src="https://static.igem.org/mediawiki/2017/1/1e/T--Chalmers-Gothenburg--Agilent.png" alt="Agilent Technologies" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,709: | Line 1,497: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="https://www.atum.bio/" target="_blank"> | <a href="https://www.atum.bio/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/a/ae/T--Chalmers-Gothenburg--ATUM_gray.png" alt="ATUM" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/7/71/T--Chalmers-Gothenburg--ATUM.png" alt="ATUM" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,716: | Line 1,504: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="http://www.chalmers.se/en/Pages/default.aspx" target="_blank"> | <a href="http://www.chalmers.se/en/Pages/default.aspx" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/9/9f/T--Chalmers-Gothenburg--Chalmers_logo_gray.png" alt="Chalmers" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/9/9f/T--Chalmers-Gothenburg--Chalmers_logo.png" alt="Chalmers" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,723: | Line 1,511: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="http://www.eurofins.com/" target="_blank"> | <a href="http://www.eurofins.com/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/f/f8/T--Chalmers-Gothenburg--eurofins_gray.png" alt="Eurofins" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/e/e4/T--Chalmers-Gothenburg--eurofins.png" alt="Eurofins" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,730: | Line 1,518: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="https://www.gatc-biotech.com/en/index.html" target=”_blank”> | <a href="https://www.gatc-biotech.com/en/index.html" target=”_blank”> | ||
− | <img src="" alt="GATC Biotech" class="footerimg on"> | + | <img src="https://static.igem.org/mediawiki/2017/c/c2/T--Chalmers-Gothenburg--gatc_gray.png" alt="GATC Biotech" class="footerimg on"> |
− | <img src="" alt="GATC Biotech" class="footerimg off"> | + | <img src="https://static.igem.org/mediawiki/2017/c/c0/T--Chalmers-Gothenburg--gatc.png" alt="GATC Biotech" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,737: | Line 1,525: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="http://www.genscript.com/" target="_blank"> | <a href="http://www.genscript.com/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/c/ce/T--Chalmers-Gothenburg--Genscript_gray.png" alt="Genscript" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/2/29/T--Chalmers-Gothenburg--Genscript.png" alt="Genscript" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,744: | Line 1,532: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="https://www.idtdna.com/" target="_blank"> | <a href="https://www.idtdna.com/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/a/a3/T--Chalmers-Gothenburg--IDT_gray.png" alt="IDT" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/f/fd/T--Chalmers-Gothenburg--IDT.png" alt="IDT" class="footerimg off"> |
+ | </a> | ||
+ | </div> | ||
+ | |||
+ | <div class="footerlogo"> | ||
+ | <a href="http://www.chalmers.se/en/areas-of-advance/lifescience/Pages/default.aspx" target="_blank"> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/6/6e/T--Chalmers-Gothenburg--Life_science_gray.png" alt="ATUM" class="footerimg on"> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/a/a3/T--Chalmers-Gothenburg--Life_science.png" alt="ATUM" class="footerimg off"> | ||
</a> | </a> | ||
</div> | </div> | ||
Line 1,751: | Line 1,546: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="https://www.neb.com/" target="_blank"> | <a href="https://www.neb.com/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/2/29/T--Chalmers-Gothenburg--neb_gray.png" alt="NEB" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/e/e6/T--Chalmers-Gothenburg--neb.png" alt="NEB" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,758: | Line 1,553: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="http://www.snapgene.com/" target="_blank"> | <a href="http://www.snapgene.com/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/1/1a/T--Chalmers-Gothenburg--SnapGene_gray.png" alt="SnapGene" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/9/95/T--Chalmers-Gothenburg--SnapGene.png" alt="SnapGene" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,765: | Line 1,560: | ||
<div class="footerlogo"> | <div class="footerlogo"> | ||
<a href="http://www.sysbio.se/" target="_blank"> | <a href="http://www.sysbio.se/" target="_blank"> | ||
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/7/7d/T--Chalmers-Gothenburg--sysbio_gray.png" alt="Sysbio" class="footerimg on"> |
− | <img src=" | + | <img src="https://static.igem.org/mediawiki/2017/8/89/T--Chalmers-Gothenburg--sysbio.png" alt="Sysbio" class="footerimg off"> |
</a> | </a> | ||
</div> | </div> | ||
Line 1,779: | Line 1,574: | ||
<a href="https://www.instagram.com/chalmersigem/" target="_blank">instagram</a> | <a href="https://www.instagram.com/chalmersigem/" target="_blank">instagram</a> | ||
</div> | </div> | ||
− | </footer> <!--------------------------------- footer_170726.html STOP ----------------------------------> | + | </footer> <!--------------------------------- footer_170726.html STOP ----------------------------------> </body> |
− | + | ||
Latest revision as of 17:28, 30 October 2017
Parts summary
Submitted parts
Table 1 shows the parts that were submitted. All biobrick parts work in S. cerevisiae and are compatible with the RFC[10] standard.
Name | Type | Description | Designer | Length |
---|---|---|---|---|
BBa_K2329000 | Regulation | Cre-lox recombination with lox66 and lox71 | Alex Hedin | 473 bp |
BBa_K2329001 | RNA | gRNA, deletion in STE2 | Alex Hedin | 388 bp |
BBa_K2329002 | RNA | gRNA, deletion in STE3 | Alex Hedin | 388 bp |
Improvement of a previous biobrick part
BBa_K2329000 is an improvement of the earlier biobrick part, BBa_K740000. The improvement of the cre-lox recombinase system was done by changing the loxP site from reversible switch to a non-reversible switch. The loxP sites flanking the promoter was changed to mutated loxP sites, see Figure 1 [1]. The new mutant loxP sites (lox66 and lox71) have showed great success since the direction of the promoter did not flip back.
![](https://static.igem.org/mediawiki/2017/e/e1/T--Chalmers-Gothenburg--LoxP_biobricks.png)
Central parts which worked as expected
BBa_K2329001 and BBa_K2329002 are two central parts of our project, as replacing the native GPCRs STE2 and STE3 is vital to ensure that the only GPCR present on the yeast cell is the heterologous GPCR introduced by us.
Non submitted parts
Table 2 shows the Basic Parts which were not submitted due to time constraints. We chose to present them here anyway to perhaps help studies for iGEM teams in the future.
Name | Type | Description | Designer | Length |
---|---|---|---|---|
BBa_K2329003 | Coding | GPCR, Ri7 | Alex Hedin | 984 bp |
BBa_K2329004 | Coding | GPCR, Olfr1258 | Alex Hedin | 936 bp |
Characterization of BBa_K2329004
BBa_K2329004 was another part that got characterized. We incorporated a mouse GPCR called Olfr1258 into S. cerevisiae which showed successful results in membrane localization and response to its ligand 2-butanone.
References
- [1] Spehr M, Munger S. Olfactory receptors: G protein-coupled receptors and beyond. Journal of Neurochemistry [Internet]. 2009 [cited 10 October 2017];109(6):1570-1583. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19383089